HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article.
Human immunodeficiency virus/hepatitis C virus (HIV/HCV) co-infection has emerged as a leading cause of liver morbidity in the last two decades. Liver failure is also frequently a cause of death in HIV/HCV co-infected patients. Highly active antiretroviral treatment (HAART) has revolutionized the HIV treatment, leading to a significantly decreased morbidity, prolonged survival, and an overall better outcome of HIV infection. Hepatotoxicity associated with antiretroviral treatment, however, has been recognized as one of the serious complications of the treatment. The effects of HIV infection on the natural history and progression of HCV-associated chronic liver disease that had been well documented in the pre-HAART treatment era have been changing, and there are now many indications that HIV/HCV co-infection should be recognized as an evolving and a challenging disease entity.
Petrovic
Lydia M
LM
Department of Pathology, New York University School of Medicine, NY, USA. lydia.petrovic@nyumc.org
D044966:Anti-Retroviral Agents / Q000009:adverse effects*; D001706:Biopsy; D016207:Cytokines / Q000378:metabolism; D005838:Genotype; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008103:Liver Cirrhosis / Q000209:etiology*; D016031:Liver Transplantation
D044966:Anti-Retroviral Agents; D016207:Cytokines